Cofactor Genomics is a cutting-edge biotechnology company specializing in RNA sequencing and advanced bioinformatics to unlock complex biological insights. They focus on developing and commercializing RNA-based diagnostics, particularly in the field of immuno-oncology, to predict patient response to therapies. Their PREDX® platform and OncoPrism® test exemplify their commitment to advancing personalized medicine by providing clinicians and researchers with powerful tools for understanding disease and improving patient outcomes. Cofactor serves pharmaceutical companies, biotech firms, and academic research institutions.
Serves as the central hub for research and development, laboratory operations, bioinformatics analysis, product development, and corporate administration.
Located in the Cortex Innovation Community, a vibrant district dedicated to bioscience and technology research, offering state-of-the-art lab facilities and fostering collaboration.
A dynamic, science-driven environment characterized by innovation, collaboration, and a strong focus on precision and quality in research and diagnostics. Employees are typically passionate about advancing healthcare through genomics.
The St. Louis headquarters, particularly its position in Cortex, is significant for its access to a skilled talent pool, proximity to Washington University and other research institutions, and a supportive ecosystem for biotech innovation.
While Cofactor Genomics's primary operations and headquarters are based in St. Louis, Missouri, USA, the company serves a global clientele. Their RNA sequencing services, bioinformatics capabilities, and diagnostic development partnerships extend to pharmaceutical companies, biotechnology firms, and academic research institutions across North America, Europe, and potentially other regions. Their data-driven solutions can be delivered and collaborated on digitally, enabling a broad reach for their specialized services.
4041 Forest Park Ave
St. Louis
Missouri
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cofactor Genomics' leadership includes:
Cofactor Genomics has been backed by several prominent investors over the years, including:
No major publicly announced executive hires or departures have been identified for Cofactor Genomics in the immediate last 12 months. The leadership team appears relatively stable based on available information. Any significant changes prior to this period would be reflected in historical news.
Discover the tools Cofactor Genomics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cofactor Genomics primarily utilizes the email format [first_initial][last]@cofactorgenomics.com. Other less common formats might exist but this is the most prevalent.
[first_initial][last]@cofactorgenomics.com
Format
jglasscock@cofactorgenomics.com
Example
85%
Success rate
GlobeNewswire • October 26, 2021
Cofactor Genomics announced a pivotal publication in The Journal for ImmunoTherapy of Cancer (JITC), validating its OncoPrism test (formerly part of the PREDX® platform as Oncoveda) as a predictor of immunotherapy response across 10 solid tumor types. The study demonstrated the test's ability to identify patients more likely to respond to immune checkpoint inhibitors....more
GenomeWeb • September 1, 2020
Cofactor Genomics announced that it has received Breakthrough Device designation from the US Food and Drug Administration for its OncoPrism diagnostic, a test that uses RNA analysis and machine learning to predict a patient's response to immunotherapy across multiple tumor types....more
BioSpace • May 15, 2019
Cofactor Genomics presented data showing its PREDX® platform, utilizing multidimensional biomarkers from RNA, more accurately predicts patient response to immunotherapies compared to existing biomarkers like PD-L1 expression and Tumor Mutational Burden (TMB)....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cofactor Genomics, are just a search away.